In this interview, a France-based KOL offers an in-depth analysis of the future use of biologics and highlights unmet needs in endpoint design for clinical trials, which could inform pipeline drug development. Additionally, the conversation covers the potential applications of Ohtuvayre, asthma-COPD overlap syndrome, and trends in COPD diagnosis rates. 

This interview was conducted on 27 May 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.